A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

Completed · Phase 3

Conditions studied: Breast Cancer

In brief

This randomized, multicenter, 2-arm, open-label study (TH3RESA) will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) in comparison with treatment of the physician's choice in participants with metastatic or unresectable locally advanced/recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Eligible participants will be randomized to receive either trastuzumab emtansine 3.6 mg/kg intravenously every 21 days or treatment of the physician's choice. Participants continue to receive study treatment until disease progression or unacceptable toxicity occurs. This study is also known under Roche study protocol number BO25734.

Key facts

Study ID

NCT01419197

Run by

Hoffmann-La Roche

People needed

602

Starts

2011-09-01

Expected to finish

2015-08-01

Last updated by the study team

2016-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult participants ≥ 18 years of age.
• Histologically or cytologically documented breast cancer.
• Metastatic or unresectable locally advanced/recurrent breast cancer.
• HER2-positive disease by prospective laboratory confirmation.
• Disease progression on the last regimen received as defined by the investigator.
• Prior treatment with an trastuzumab, a taxane, and lapatinib.
• Disease progression after at least two regimens of HER2-directed therapy in the metastatic or unresectable locally advanced/recurrent setting.
• Adequate organ function, as evidenced by laboratory results.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or multi gated acquisition scan.

You may not qualify if…

• Chemotherapy ≤ 21 days before first study treatment.
• Trastuzumab ≤ 21 days before first study treatment.
• Lapatinib ≤ 14 days before first study treatment.
• Prior enrollment in a trastuzumab emtansine containing study, regardless whether the patient received prior trastuzumab emtansine.
• Brain metastases that are untreated or symptomatic, or require any radiation, surgery or corticosteroid therapy to control symptoms within 1 month of randomization.

Where it is running

• Study site — Hot Springs, Arkansas, United States
• Study site — Hayward, California, United States
• Study site — Highland, California, United States
• Study site — Oakland, California, United States
• Study site — Roseville, California, United States
• Study site — Sacramento, California, United States
• Study site — San Diego, California, United States
• Study site — San Francisco, California, United States
• Study site — San Jose, California, United States
• Study site — Santa Clara, California, United States
• Study site — South San Francisco, California, United States
• Study site — Stockton, California, United States
• Study site — Vallejo, California, United States
• Study site — Walnut Creek, California, United States
• Study site — West Hollywood, California, United States
• Study site — Denver, Colorado, United States
• Study site — Trumbull, Connecticut, United States
• Study site — Newark, Delaware, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Coral Springs, Florida, United States
• Study site — Deerfield Beach, Florida, United States
• Study site — Fort Myers, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — Plantation, Florida, United States
• Study site — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.